GENETIC ADJUVANTS FOR IMMUNOTHERAPY
    71.
    发明申请
    GENETIC ADJUVANTS FOR IMMUNOTHERAPY 失效
    遗传性免疫缺陷症

    公开(公告)号:US20090280143A1

    公开(公告)日:2009-11-12

    申请号:US12476896

    申请日:2009-06-02

    摘要: The present invention pertains to methods and pharmaceutical compositions for modulating an immune response. The method of the present invention involves administration of an effective amount of nucleic acid molecules encoding interleukin-12 (IL-12), interferon-gamma (IFN-γ), or a combination thereof, to a patient in need of such treatment. The pharmaceutical compositions of the invention contain nucleic acid molecules encoding IL-12 and/or IFN-γ and an operably-linked promoter sequence. In another aspect, the present invention concerns expression vectors containing a nucleotide sequence encoding IL-12 and IFN-γ, and an operably-linked promoter sequence. In another aspect, the present invention concerns cells genetically modified with a nucleotide sequence encoding IL-12 and IFN-γ.

    摘要翻译: 本发明涉及用于调节免疫应答的方法和药物组合物。 本发明的方法涉及向需要这种治疗的患者施用有效量的编码白细胞介素-12(IL-12),干扰素-γ(IFN-γ)或其组合的核酸分子。 本发明的药物组合物含有编码IL-12和/或IFN-γ的核酸分子和可操作地连接的启动子序列。 另一方面,本发明涉及含有编码IL-12和IFN-γ的核苷酸序列和可操作地连接的启动子序列的表达载体。 另一方面,本发明涉及用编码IL-12和IFN-γ的核苷酸序列遗传修饰的细胞。

    Climate control duct architecture for a vehicle
    72.
    发明申请
    Climate control duct architecture for a vehicle 有权
    用于车辆的气候控制管道结构

    公开(公告)号:US20090270022A1

    公开(公告)日:2009-10-29

    申请号:US12148833

    申请日:2008-04-23

    IPC分类号: B60H1/26

    摘要: A climate control duct architecture having partitions to provide effective distribution of air immediately as it exits the HVAC. By strategic positioning and configuring of the partitions the duct architecture may be tuned to provide maximum console airflow and desired system airflow distribution with a minimum amount of interference to the airflow due to turbulence.

    摘要翻译: 一种气候控制管道结构,具有隔板,以便在离开暖通空调时立即提供有效的空气分配。 通过战略定位和配置分区,管道架构可以被调整以提供最大的控制台气流和期望的系统气流分布,由于湍流对气流具有最小量的干扰。

    PROLIPOSOMAL AND LIPOSOMAL COMPOSITIONS OF POORLY WATER SOLUBLE DRUGS
    73.
    发明申请
    PROLIPOSOMAL AND LIPOSOMAL COMPOSITIONS OF POORLY WATER SOLUBLE DRUGS 审中-公开
    不溶性水溶性药物的组成和脂质组成

    公开(公告)号:US20090017105A1

    公开(公告)日:2009-01-15

    申请号:US12045958

    申请日:2008-03-11

    IPC分类号: A61K9/127 A61P35/00

    摘要: Concentrates or proliposomal compositions of poorly water-soluble drugs and compounds, comprising of one or more membrane forming lipids, a membrane stabilizing agent, in a suitable vehicle, and optionally containing a Polyethylene Glycol (PEG)-coupled phospholipid or a mixture thereof and further, optionally containing pharmaceutically acceptable excipients such as antioxidants, buffering agents, acidifying agents etc. are provided, which have superior long term stability. The concentrates of proliposomal compositions instantly form liposomes of the said poorly water-soluble drugs and compounds on rapid injection to a diluting fluid, the liposomal composition so obtained, characterized by a physical stability more than 24 hours, ≧95% drug encapsulation and having a particle size diameter of less than 100 nm. The liposomal compositions so obtained can further be directly administered to patients in need of treatment of the poorly water-soluble drugs and compounds.

    摘要翻译: 水溶性差的药物和化合物的浓缩物或前体组合物,包含一种或多种形成膜的脂质,膜稳定剂,在合适的载体中,并且任选地含有聚乙二醇(PEG) - 偶联的磷脂或其混合物 ,任选地含有药学上可接受的赋形剂如抗氧化剂,缓冲剂,酸化剂等,其具有优异的长期稳定性。 促乳素体组合物的浓缩物立即形成所述水难溶性药物和化合物的脂质体,其快速注射至稀释液体,如此获得的脂质体组合物,其特征在于物理稳定性超过24小时,> = 95%药物包封并具有 粒度直径小于100nm。 如此获得的脂质体组合物可以进一步直接施用于需要治疗不良水溶性药物和化合物的患者。

    Disodium pamidronate formulation
    76.
    发明申请
    Disodium pamidronate formulation 审中-公开
    帕米膦酸二钠制剂

    公开(公告)号:US20060217350A1

    公开(公告)日:2006-09-28

    申请号:US11245389

    申请日:2005-10-06

    IPC分类号: A61K31/66

    摘要: A stable pharmaceutical composition comprising a solution of disodium pamidronate in an aqueous solvent and a process for the preparation thereof. The solution of disodium pamidronate is free of particulate matter and has an alkaline pH. The process for preparation of the stable pharmaceutical composition comprises adding disodium pamidronate and optionally a sugar into an aqueous solvent; heating the said mixture at a temperature in the range of 50° C. to 90° C. to obtain a clear solution. It is cooled to ambient temperature, filtered, filled and stored in a conventional and untreated glass container and sealed with normal elastomeric closure. The sealed container is sterilized by steam sterilization.

    摘要翻译: 一种稳定的药物组合物,其包含在水性溶剂中的帕米膦酸二钠溶液及其制备方法。 帕米膦酸二钠的溶液不含颗粒物质,具有碱性pH。 制备稳定的药物组合物的方法包括将帕米膦酸二钠和任选的糖加入到含水溶剂中; 在50℃至90℃的温度下加热所述混合物以获得澄清溶液。 将其冷却至环境温度,过滤,填充并储存在常规和未处理的玻璃容器中并用正常弹性封闭物密封。 密封容器通过蒸汽灭菌灭菌。

    Method and apparatus for preparing bone
    77.
    发明申请
    Method and apparatus for preparing bone 审中-公开
    骨的制备方法及装置

    公开(公告)号:US20060083769A1

    公开(公告)日:2006-04-20

    申请号:US10964950

    申请日:2004-10-14

    IPC分类号: A61K35/32 A61F2/00

    摘要: Formed compositions for application to a bone surface of a human or animal subject, comprising: a bone material; and a carrier comprising denatured demineralized bone, where the composition is formed into a shape suitable for administration to the bone. Methods are provided for making formed compositions for application to a bone surface of a human or animal subject comprise mixing a demineralized bone and water; heating the mixture to form a carrier; mixing the carrier with bone to form a moldable composition; and molding the moldable composition to produce a formed composition. Apparatus are provided comprising a retaining tube and a hydrating tube. Methods of hydrating a formed bone composition are also provided.

    摘要翻译: 用于施用于人或动物受试者的骨表面的成形组合物,包括:骨材料; 以及包含变性软化骨的载体,其中所述组合物形成适于施用于骨的形状。 提供用于制备用于施用于人或动物对象的骨表面的成形组合物的方法包括混合脱矿质骨和水; 加热混合物形成载体; 将载体与骨混合以形成可成型组合物; 并模塑可模制组合物以产生形成的组合物。 提供了包括保持管和水合管的装置。 还提供了水合形成的骨组合物的方法。

    Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection
    78.
    发明申请
    Interrupting the interaction of intercellular adhesion molecule-1 and respiratory syncytial virus for prevention and treatment of infection 审中-公开
    中断细胞间粘附分子-1和呼吸道合胞病毒的相互作用,用于预防和治疗感染

    公开(公告)号:US20050158327A1

    公开(公告)日:2005-07-21

    申请号:US11079834

    申请日:2005-03-14

    摘要: There is provided a method of preventing a respiratory infection by administering an effective amount of an agent for regulating ICAM-1 expression. Also provided is a composition for the prevention of respiratory infection including an agent which regulates ICAM expression. Also provided is a method of preventing RSV infection by administering an effective amount of an agent that interferes with the binding of RSV to ICAM-1. A method of preventing RSV infection by administering an effective amount of an agent that down regulates the expression of ICAM-1, thereby decreasing RSV binding to ICAM-1 is also provided. There is provided a method of treating RSV infection by administering an effective amount of an agent for down regulating ICAM-1 expression. A method of blocking RSV-ICAM-1 interaction by administering an effective amount of agents for blocking ICAM sites of binding is provided. Also provided is a compound for blocking RSV-ICAM-1 interaction including an agent for blocking ICAM sites of binding.

    摘要翻译: 提供了一种通过施用有效量的用于调节ICAM-1表达的试剂来预防呼吸道感染的方法。 还提供了用于预防呼吸道感染的组合物,包括调节ICAM表达的药剂。 还提供了通过施用有效量的妨碍RSV与ICAM-1的结合的试剂来预防RSV感染的方法。 还提供了通过施用有效量的下调ICAM-1的表达的试剂,从而降低RSV与ICAM-1的结合来预防RSV感染的方法。 提供了通过施用有效量的用于下调ICAM-1表达的试剂来治疗RSV感染的方法。 提供了通过施用有效量的阻断ICAM结合位点的试剂阻断RSV-ICAM-1相互作用的方法。 还提供了用于阻断RSV-ICAM-1相互作用的化合物,其包括用于阻断结合的ICAM位点的试剂。

    Pump pressure limiting method
    79.
    发明授权
    Pump pressure limiting method 有权
    泵压力限制方法

    公开(公告)号:US06904762B2

    公开(公告)日:2005-06-14

    申请号:US10685197

    申请日:2003-10-14

    摘要: A novel pump pressure limiting method for preventing coolant in a cooling system from reaching pressures that exceed predetermined system coolant pressure limits. The method includes reducing the system coolant pressure, as needed to prevent system over-pressurization, by reducing the operational speed of a coolant pump used to pump the coolant through the system. In one embodiment, the system coolant pressure is determined directly, by measurement of the pressure of the coolant in the system typically using pressure sensors. The operational speed of the coolant pump is then reduced until the system coolant pressure decreases to within the predetermined pressure limits. In another embodiment, the system pressure is determined indirectly, by obtaining pressure-indicating data such as coolant temperature. The coolant system pressure is then correlated with the coolant temperature or other data and then the operational speed of the coolant pump is reduced accordingly.

    摘要翻译: 一种用于防止冷却系统中的冷却剂达到超过预定系统冷却剂压力极限的压力的新型泵压力限制方法。 该方法包括通过降低用于泵送冷却剂通过系统的冷却剂泵的操作速度,根据需要降低系统冷却剂压力以防止系统过压。 在一个实施例中,通过使用压力传感器测量系统中的冷却剂的压力来直接确定系统冷却剂压力。 然后冷却剂泵的操作速度降低,直到系统冷却剂压力降低到预定压力极限内。 在另一个实施例中,通过获得诸如冷却剂温度的压力指示数据来间接确定系统压力。 然后将冷却剂系统压力与冷却剂温度或其他数据相关联,然后相应地减小冷却剂泵的操作速度。

    Ceramic implants affording controlled release of active materials

    公开(公告)号:US10010500B2

    公开(公告)日:2018-07-03

    申请号:US12195789

    申请日:2008-08-21

    申请人: Mukesh Kumar

    发明人: Mukesh Kumar

    CPC分类号: A61K9/0024 A61K9/5031

    摘要: Implantable compositions providing release of bioactive agents according to a predetermined release profile and methods for their use. Such compositions include at least one ceramic substrate; a bioactive substance loaded on a surface of the ceramic substrate forming a loaded surface zone operable to release said bioactive substance according to a release profile under physiological conditions; and a biodegradable polymer having an in vivo degradation period, forming a continuous or discontinuous coating on an area of the ceramic substrate.